Financial Contrast: Agios Pharmaceuticals (AGIO) and Its Rivals
Agios Pharmaceuticals (NASDAQ: AGIO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Agios Pharmaceuticals to related companies based on the strength of its risk, dividends, analyst recommendations, earnings, institutional ownership, profitability and valuation.
This table compares Agios Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Agios Pharmaceuticals Competitors||-5,356.97%||-433.60%||-39.05%|
This is a breakdown of recent ratings and target prices for Agios Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Agios Pharmaceuticals Competitors||845||3195||11582||230||2.71|
Agios Pharmaceuticals presently has a consensus price target of $75.70, suggesting a potential upside of 23.43%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.79%. Given Agios Pharmaceuticals’ competitors higher possible upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its competitors.
Volatility & Risk
Agios Pharmaceuticals has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ competitors have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.
Institutional and Insider Ownership
94.4% of Agios Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Agios Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agios Pharmaceuticals||$69.89 million||-$198.47 million||-9.78|
|Agios Pharmaceuticals Competitors||$284.28 million||$34.29 million||134.59|
Agios Pharmaceuticals’ competitors have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.